Safety and pharmacokinetics of intravaginal rings delivering tenofovir in pig-tailed macaques

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 11, 2012, Pages 5952-5960

  Moss, John A ^a   Malone, Amanda M ^b   Smith, Thomas J ^a,b   Butkyavichene, Irina ^b   Cortez, Cassandra ^a,b   Gilman, Joshua ^b   Kennedy, Sean ^a   Kopin, Etana ^b   Nguyen, Cali ^a,b   Sinha, Preetha ^a   Michael Hendry, R ^c   Guenthner, Patricia ^c   Holder, Angela ^c   Martin, Amy ^c   McNicholl, Janet ^c   Mitchell, James ^c   Pau, Chou Pong ^c   Srinivasan, Priya ^c   Smith, James M ^c   Baum, Marc M ^a  

^a OAK CREST INSTITUTE OF SCIENCE   (United States)

^b Auritec Pharmaceuticals Inc   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TENOFOVIR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; INTRAVAGINAL RING; LYMPHOCYTE; MACACA NEMESTRINA; NONHUMAN; PRIORITY JOURNAL; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SUSTAINED DRUG RELEASE; VAGINAL SECRETION; VIRUS STRAIN; VIRUS TRANSMISSION;

ADENINE; ADMINISTRATION, INTRAVAGINAL; ANIMALS; CONTRACEPTIVE DEVICES, FEMALE; CYTOKINES; DELAYED-ACTION PREPARATIONS; FEMALE; HALF-LIFE; LYMPHOCYTES; MACACA NEMESTRINA; ORGANOPHOSPHONATES; REVERSE TRANSCRIPTASE INHIBITORS; VAGINA;

EID: 84868035130     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01198-12     Document Type: Article

References (50)

1. Anderson PL, et al. 2011. Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. J. Antimicrob. Chemother. 66:240-250.
2. Anglewicz PA, Bignami-Van Assche S, Clark S, Mkandawire J. 2010. HIV risk among currently married couples in rural Malawi: what do spouses know about each other? AIDS Behav. 14:103-112.
3. Barditch-Crovo P, et al. 2001. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob. Agents Chemother. 45:2733-2739.
4. Baum MM, et al. 2012. An intravaginal ring for the simultaneous delivery of multiple drugs. J. Pharm. Sci. 101:2833-2843.
5. D'Cruz OJ, Uckun FM. 2004. Clinical development of microbicides for the prevention of HIV infection. Curr. Pharm. Des. 10:315-336.
6. Dobard C, et al. 2012. Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue. J. Virol. 86: 718-725.
7. Dunkle KL, et al. 2008. New heterosexually transmitted HIV infections in married or cohabiting couples in urban Zambia and Rwanda: an analysis of survey and clinical data. Lancet 371:2183-2191.
8. Durand-Gasselin L, et al. 2009. Nucleotide analogue prodrug tenofovir disoproxil enhances lymphoid cell loading following oral administration in monkeys. Mol. Pharm. 6:1145-1151.
9. Eyawo O, et al. 2010. HIV status in discordant couples in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Infect. Dis. 10:770-777.
10. Garcia-Lerma JG, et al. 2010. Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. Sci. Transl. Med. 2:14ra4. doi:10.1126/scitranslmed.3000391.
11. Geonnotti AR, Katz DF. 2010. Compartmental transport model of microbicide delivery by an intravaginal ring. J. Pharm. Sci. 99:3514-3521.
12. Grant RM, et al. 2010. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 363:2587-2599.
13. Gunawardana M, et al. 2011. Microbial biofilms on the surface of intravaginal rings worn in non-human primates. J. Med. Microbiol. 60:828-837.
14. Guthrie BL, et al. 2009. Sexually transmitted infections among HIV-1-discordant couples. PLoS One 4:e8276. doi:10.1371/journal. pone.0008276.
15. Hawkins T, et al. 2005. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J. Acquir. Immune Defic. Syndr. 39:406-411.
16. Hecht R, et al. 2010. Financing of HIV/AIDS programme scale-up in low-income and middle-income countries, 2009-31. Lancet 376:1254-1260.
17. Hendrix CW, Cao YJ, Fuchs EJ. 2009. Topical microbicides to prevent HIV: clinical drug development challenges. Annu. Rev. Pharmacol. Toxicol. 49:349-375.
18. Ingle JD, Crouch SR. 1988. Spectrochemical analysis. Prentice Hall, Old Tappan, NJ.
19. Johnson TJ, et al. 2012. Safe and sustained vaginal delivery of pyrimidinedione HIV-1 inhibitors from polyurethane intravaginal rings. Antimicrob. Agents Chemother. 56:1291-1299.
20. Karim QA, et al. 2010. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329:1168-1174.
21. Karim SSA, Kashuba ADM, Werner L, Karim QA. 2011. Drug concentrations After topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet 378:279-281.
22. Kiser PF, Johnson TJ, Clark JT. 2012. State of the art in intravaginal ring technology for topical prophylaxis of HIV infection. AIDS Rev. 14:62-77.
23. Klasse PJ, Shattock RJ, Moore JP. 2006. Which topical microbicides for blocking HIV-1 transmission will work in the real world? PLoS Med. 3:e351. doi:10.1371/journal.pmed.0030351.
24. Kuklenyik Z, et al. 2009. Effect of mobile phase pH and organic content on LC-MS analysis of nucleoside and nucleotide HIV reverse transcriptase inhibitors. J. Chromatogr. Sci. 47:365-372.
25. Kuklenyik Z, et al. 2009. On-line coupling of anion exchange and ionpair chromatography for measurement of intracellular triphosphate metabolites of reverse transcriptase inhibitors. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877:3659-3666.
26. London S. 2008. Most heterosexual HIV transmission in urban Rwanda and Zambia occurs in married or cohabiting couples. Int. Fam. Plan. Perspect. 34:146.
27. Malcolm RK, Edwards KL, Kiser P, Romano J, Smith TJ. 2010. Advances in microbicide vaginal rings. Antiviral Res. 88:S30-S39.
28. Moss JA, et al. 2010. In vitro release of tenofovir and acyclovir from a silicone vaginal ring platform, abstr 259. Abstr. Microbicides 2010, Pittsburgh, PA, 22 to 26 May 2010.
29. Moss JA, et al. 2012. Tenofovir and tenofovir disoproxil pharmacokinetics from intravaginal rings. AIDS 26:707-710.
30. Moss JA, et al. 2012. Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring. Antimicrob. Agents Chemother. 56:875-882.
31. National Research Council. 2011. Guide for the care and use of laboratory animals. Department of Health, Education, and Welfare (DHEW) publication no. NIH 86-23. The National Academies Press, Washington, DC.
32. Nel A, et al. 2009. Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. J. Acquir. Immune Defic. Syndr. 51:416-423.
33. Nuttall J, et al. 2012. The pharmacokinetics of tenofovir following intravaginal and intrarectal administrationoftenofovir geltorhesus macaques. Antimicrob. Agents Chemother. 56:103-109.
34. Owen DH, Katz DF. 1999. A vaginal fluid simulant. Contraception 59: 91-95.
35. Parikh UM, et al. 2009. Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel Containing tenofovir alone or with emtricitabine. J. Virol. 83:10358-10365.
36. Patton DL, Sweeney YC, Rabe LK, Hillier SL. 1996. The vaginal microfloraofpig-tailed macaques and the effectsofchlorhexidine and benzalkonium on this ecosystem. Sex. Transm. Dis. 23:489-493.
37. Patton DL, Sweeney YTC, Paul KJ. 2008. A summary of preclinical topical microbicide vaginal safety and chlamydial efficacy evaluations in a pigtailed macaque model. Sex. Transm. Dis. 35:889-897.
38. Promadej-Lanier N, et al. 2009. Development and evaluation of a vaginal ring device for sustained delivery of HIV microbicides to non-human primates. J. Med. Primatol. 38:263-271.
39. Pruvost A, et al. 2005. Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 49:1907-1914.
40. Romano J, et al. 2009. Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. AIDS Res. Hum. Retrovir. 25:483-488.
41. Saxena BB, et al. 2009. Sustained release of microbicides by newly engineered vaginal rings. AIDS 23:917-922.
42. Shattock RJ, Warren M, McCormack S, Hankins CA. 2011. Turning the tide against HIV. Science 333:42-43.
43. Smith DJ, et al. 2008. An evaluation of intravaginal rings as a potential HIV prevention devicein urban Kenya: behaviors and attitudes that might influence uptake within a high-risk population. J. Womens Health (Larchmt.) 17:1025-1034.
44. Spear GT, et al. 2010. Identification of rhesus macaque genital microbiota by 16S pyrosequencing shows similarities to human bacterial vaginosis: implications for use as an animal model for HIV vaginal infection. AIDS Res. Hum. Retroviruses 26:193-200.
45. Stein DS, Moore KHP. 2001. Phosphorylation of nucleoside analog antiretrovirals: a review for clinicians. Pharmacotherapy 21:11-34.
46. Valenta C. 2005. The use of mucoadhesive polymers in vaginal delivery. Adv. Drug Deliv. Rev. 57:1692-1712.
47. Van Rompay KKA. 2010. Evaluation of antiretrovirals in animal models of HIV infection. Antiviral Res. 85:159-175.
48. Veazey RS. 2008. Microbicide safety/efficacy studies in animals - macaques and small animal models. Curr. Opin. HIV AIDS 3:567-573.
49. Yoo JW, Lee CH. 2006. Drug delivery systems for hormone therapy. J. Control. Release 112:1-14.
50. Yu RR, et al. 2009. A Chinese rhesus macaque (Macaca mulatta) model for vaginal lactobacillus colonization and live microbicide development. J. Med. Primatol. 38:125-136.